四价人乳头瘤病毒疫苗致外阴溃疡1例分析

doi:10.19803/j.1672-8629.20250415

摘要/Abstract

摘要： 目的探讨四价人乳头瘤病毒（HPV）疫苗致外阴溃疡不良反应,为疫苗安全性接种提供参考。方法结合国内外文献,分析1例疑似接种四价HPV疫苗后引起的外阴溃疡病例,讨论不良反应发生可能机制及其处置措施。结果本例患者既往健康,无相关疾病史,接种四价HPV疫苗后出现外阴溃疡等不良反应,经关联性分析,外阴溃疡疑似为接种四价HPV疫苗引起的不良反应。抗感染治疗后,患者好转出院。结论接种四价HPV疫苗后,应密切关注相关不良反应,若发生外阴溃疡,需及时实施治疗干预。

关键词: 人乳头瘤病毒疫苗, 四价, 接种, 外阴溃疡, 不良反应

Abstract: Objective To investigate one case of vulvar ulcer suspected to be caused by the recombinant human papillomavirus quadrivalent (types 6,11,16,18) vaccine (4v hpv vaccine) so as to provide a reference for safe vaccination. Methods The clinical data of one patient who developed vulvar ulcer after receiving the 4v hpv vaccine was analyzed while related literature was reviewed to identify the possible causes and manage this adverse reaction. Results The patient used to be healthy with no related medical history. Vulvar ulcer was considered to be an adverse reaction associated with the 4v hpv vaccine. After anti-infection treatment, the patient improved and was discharged. Conclusion After vaccination with the 4v hpv vaccine, monitoring of vaccine-related adverse reactions is essential, and immediate therapeutic interventions are recommended in the event of vulvar ulcers.

Key words: Human Papillomavirus Vaccine, Quadrivalent, Vaccination, Vulvar Ulcer, Adverse Reaction

中图分类号:

R978
R994.11

高鑫. 四价人乳头瘤病毒疫苗致外阴溃疡1例分析[J]. 中国药物警戒, 2026, 23(6): 693-695.

GAO Xin. One Case of Vulvar Ulcer Caused by Recombinant Human Papillomavirus Quadrivalent Vaccine[J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 693-695.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250415

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I6/693

参考文献

[1] SHEN LP, XU YQ.The Clinical Relationship of the CHD1L and ECRG4 Protein’s Expression in Cervical Cancer Tissue and the Infection of HR-HPV[J]. Maternal and Child Health Care of China(中国妇幼保健), 2023, 38(8): 1499-1502.
[2] PEI ZC, LI H, SHEN X, et al.Literature Review of 1 Case of Severe Eczema Caused by Human Papillomavirus Vaccine[J]. Chinese Journal of Nosocomiology(中华医院感染学杂志), 2024, 34(14): 2144-2148.
[3] DHILLON SK, COCUZZA CE, CHUNG PYJ, et al.Evaluation of the Clinical Performance of Oncopredict HPV (^®SCR) Assay within the Valgent-2 Framework[J]. Journal of Medical Virology, 2023, 95(1): e28417.
[4] MEI XX, LIN NY, MA CG, et al.Research Progress on the Prevention and Treatment of HPV Infection-Related Diseases on Mucosal Sites[J]. Journal of Diagnosis and Therapy on Dermato-Venereology(皮肤性病诊疗学杂志), 2022, 29(5): 487-489.
[5] Society of Gynecologic Oncology, Chinese Medical Association; Branch of Colposcopy and Cervical Pathology, China Healthy Birth Science Association; Professional Committee on Cancer Prevention and Control Chinese Preventive Medicine Association; et al. Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China (2025 Edition)[J]. Medical Journal of Peking Union Medical College Hospital(协和医学杂志), 2025, 16(2): 350-360.
[6] Chinese Preventive Medicine Association, Vaccine and Immunization Branch. Chinese Preventive Medicine Association. Expert Consensus on Immunoprophylaxis of Cervical Cancer and Other Human Papillomavirus-Related Diseases (2025 Edition)[J]. Chinese Journal of Preventive Medicine(中国预防医学杂志),2025, 26(7): 1-38.
[7] GONG L.A Preliminary Study on Post-Marketing Safety of Preventive Human Papillomavirus Vaccine[J]. Electronic Journal of Chongqing Medical University(重庆医科大学电子期刊), 2020(12): 1-96.
[8] MHRA. Medicines, Medical Devices[DB/OL]. [2025-07-16].https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood#research_and_statistics.
[9] WHO. Vigiaccess[DB/OL].[2025-07-16]. https://www.vigiaccess.org/.
[10] LI MZ, ZHAO C, ZHAO Y, et al.Immunogenicity, Efficacy, and Safety of Human Papillomavirus Vaccine: Data from China[J]. Frontiers in Immunology, 2023, 14: 1112750.
[11] NEHA R, SUBEESH V, BEULAH E, et al.Postlicensure Surveillance of Human Papillomavirus Vaccine Using the Vaccine Adverse Event Reporting System, 2006-2017[J]. Perspectives in Clinical Research, 2020, 11(1): 24-30.
[12] WANG RJ, PAN W, JIN L, et al.Human Papillomavirus Vaccine against Cervical Cancer: Opportunity and Challenge[J]. Cancer Letters, 2020, 471: 88-102.
[13] LIU S, ZHANG DX, LI L, et al.Clinical Observation of HE-NE Laser Irradiation Combined with Moist Exposed Burn Ointment in Treatment of 32 Cases with Ulcus Vulvae[J]. Journal of Youjiang Medical University for Nationalities(右江民族医学院学报), 2015, 37(2): 270-271.
[14] HUA XL, WANG Y, ZHANG HS, et al.A Study on the Relationship between Vulvar Ulcers and Female Endocrine Hormone Levels[J].Electronic Journal of Practical Gynecological Endocrinology(实用妇科内分泌电子杂志), 2024 , 11(15): 34-36.
[15] OUYANG L.Study the Association of Perfluorinated Compounds Exposure Levels in Serum and Follicular Fluid of Infertile Women with Assisted Reproductive Pregnancy Outcomes[J]. Electronic Journal of Zhengzhou University(郑州大学电子期刊), 2019(8): 1-63.